SCHEMBL3088068

SCHEMBL3088068

[CH2]Cc1cnccc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
FAAH O00519 1/20 0.36
IDO1 P14902 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PRKCQ Q04759 4/20 0.36
PRKCD Q05655 2/20 0.36
MAPT P10636 1/20 0.35
CD38 P28907 1/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
SCD5 Q86SK9 2/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
SCD O00767 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095325 0.85 GRIN1 (0.36) GRIN1GRIN2BFAAHALDH1A1PRKCQ
SCHEMBL507313 0.80 LOXL2 (0.52) GRIN1GRIN2BFAAHIDO1ALDH1A1
SCHEMBL30630670 0.80 LOXL2 (0.52) GRIN1GRIN2BFAAHIDO1ALDH1A1
SCHEMBL15514881 0.80 CD38 (0.40) GRIN1GRIN2BFAAHALDH1A1MAPT
SCHEMBL8403256 0.80 ALDH1A1 (0.48) GRIN1GRIN2BFAAHALDH1A1MAPT
SCHEMBL1272973 0.80 GRIN1 (0.40) GRIN1GRIN2BFAAHALDH1A1PRKCQ
SCHEMBL844759 0.80 GRIN1 (0.37) GRIN1GRIN2BFAAHALDH1A1PRKCQ
SCHEMBL29525334 0.80 CD38 (0.40) GRIN1GRIN2BFAAHALDH1A1PRKCQ
SCHEMBL1272312 0.80 CD38 (0.40) GRIN1GRIN2BFAAHALDH1A1PRKCQ
Hydrochloric Acid SCHEMBL30162975 0.78 AOC3 (0.50) GRIN1GRIN2BFAAHIDO1CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9532985-B2 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders ACTELION PHARMACEUTICALS LTD. (CH) 2017-01-03 US disclosed
EP-2207550-B1 TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS ACTELION PHARMACEUTICALS LTD (CH) 2013-12-11 EP disclosed
US-20100234420-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS IDORSIA PHARMACEUTICALS LTD (CH) 2010-09-16 US disclosed
EP-2207550-A2 TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS Actelion Pharmaceuticals Ltd. (CH) 2010-07-21 EP disclosed
WO-2009047723-A2 TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS ACTELION PHARMACEUTICALS LTD (CH) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234420-A1 TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS CRH, HTR2C, CRHR1 GRIN1 108/4885GRIN2B 139/4885FAAH 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.